Here we report the anticancer efficacy of an oncolytic MyxV simultaneously expressing CD47, to avoid an antiviral immune response, and IFN-γ, to boost effective anti-tumoral immunity as a stand-alone treatment, or with αPD-L1 combination therapy in melanoma models. This evidence concerns the gene IFNG and melanoma.